US Stock MarketDetailed Quotes

DMAC DiaMedica Therapeutics

Watchlist
  • 5.655
  • +0.445+8.54%
Close Nov 29 13:00 ET
  • 5.655
  • 0.0000.00%
Post 13:02 ET
241.81MMarket Cap-10098P/E (TTM)

DiaMedica Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

DiaMedica Therapeutics Q3 2024 Earnings Date

Currency：USDNov 13, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
0
0
0
--
--
--
EPS
-0.15
-0.15
+<0.01
Beat Est.
-29.19%
-25.00%
+3.16%
Analyst Rating
Strong Buy

Oct 7, 2024

DiaMedica Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: CAD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 13, 20242024/Q30.000 / 0.000--
Aug 7, 20242024/Q20.000 / 0.000--
May 8, 20242024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 13, 20242024/Q30.000 / 0.000--
Aug 7, 20242024/Q20.000 / 0.000--
May 8, 20242024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

DiaMedica Therapeutics Earnings Reports

  • DiaMedica Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 14 05:29

  • DiaMedica Therapeutics | 8-K: DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

    Nov 14 05:26

  • DiaMedica Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 8 04:37

  • DiaMedica Therapeutics | 8-K: DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

    Aug 8 04:37

    • Read more

    Analysis

    Analyst Rating

    Updated: Oct 7, 2024

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data